

- **Pregnancy/breastfeeding:** Pregnancy should be avoided during and for at least 1 month after the last dose; obtain pregnancy testing before use

Evaluate:

- Therapeutic response: decreased progression of cancer

Teach patient/family:

- About the reproductive risk and contraception requirements during treatment; men with female partners of reproductive potential should also use effective contraception during treatment and for 1 month after the last dose; not to breast-feed during and for 1 month after last dose
- Ophthalmic examinations will be needed periodically

esketamine (Rx)

(es- ket'-a- meen)

Spravato nasal spray*Func. class.:* Antidepressant*Chem. class.:* Augmentation agent

Controlled substance III

ACTION: Noncompetitively blocks the NMDA receptor, which is an ionotropic glutamate receptor; mechanism of action for antidepressant effect is unknown; however, the activity on NMDA receptors may be responsible for both the therapeutic and the adverse psychiatric effects

USES: Treatment-resistant depression in adults with an oral antidepressant

CONTRAINDICATIONS

Aneurysm, arteriovenous malformation, intracranial bleeding, ketamine hypersensitivity

Precautions:

Alcoholism, breastfeeding, cardiac disease, cerebrovascular disease, coadministration with other CNS depressants, driving or operating machinery, encephalopathy, geriatrics, hepatic disease, hypertension, hypertensive crisis, loss of consciousness, pregnancy, psychosis, schizophrenia

Black Box Warning: Children, CNS depression, dissociation, requires a specialized care setting, substance abuse, suicidal ideation

DOSAGE AND ROUTES

Adults: NASAL INDUCTION PHASE: On day 1, give 56 mg; for subsequent doses during wk 1 through 4, give 56 mg or 84 mg twice weekly; use two devices for the 56-mg dose and 3 devices for the 84-mg dose with a 5-min rest between use of each device; **MAINTENANCE PHASE:** During wk 5 through 8, give 56 mg or 84 mg weekly; during wk 9 and thereafter, give 56 mg or 84 mg q2wks or weekly.

Available forms: Nasal spray 56, 84 dose kit

Administer: Nasal Route

- Must be given under the direct supervision of a healthcare provider and including a supervised postadministration observation
- Each device contains 28 mg; use 2 devices for a 56-mg dose and 3 devices for an 84-mg dose with a 5-min rest between use of each device
- To prevent loss of medication, do not prime the device before use
- During and after use at each treatment session, observe the patient for at least 2 hr until the patient is safe to leave
- Assess B/P before use; if baseline B/P > 140 mm Hg systolic or >90 mm Hg diastolic, do not use if an increase in B/P or intracranial pressure poses a serious risk
- Reassess B/P about 40 min after dosing and subsequently as clinically indicated; if B/P is decreasing and the patient appears clinically stable for at least 2 hr, the patient may be discharged at the end of the post-dose monitoring period; if not, continue to monitor.
- Because of the potential for drug-induced nausea and vomiting, advise patients to avoid food for at least 2 hr before use and avoid liquids at least 30 min before administration
- Patients requiring a nasal corticosteroid or nasal decongestant on dosing day